盘状结构域受体2：癌症中的新靶点。
Discoidin Domain Receptor 2: A New Target in Cancer.
作者信息
Xu Xiaoxiao, Yu Tong, Wang Zhenxing
机构信息
Department of Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Department of Stem Cells and Regenerative Medicine, College of Basic Medical Science, China Medical University, Shenyang, China.
出版信息
Oncol Res Treat. 2022;45(4):205-215. doi: 10.1159/000519645. Epub 2022 Jan 24.
BACKGROUND
Discoidin domain receptor is a new and unique type of receptor tyrosine kinases, which binds to collagen, the main compose of an extracellular matrix. DDR1 was identified to mediate cell aggregation, and dysregulation of DDR2 has also been shown to be involved in tumor pathogenesis, although its role in cancer development and progression remains controversial.
SUMMARY
Abnormal expression and mutations of DDR2 have been reported in several cancer types and its participation in different aspects of tumor progression, including proliferation, migration, invasion, metastasis, epithelial-mesenchymal transition, and chemotherapy resistance. Moreover, novel DDR2 inhibitors have been designed and indicate a therapeutic effect for the cancer treatment.
KEY MESSAGES
In this review, we summarize the current knowledge on the role of DDR2 in cancer promotion and the potential therapeutic value of targeting DDR2.
背景
盘状结构域受体是一种新型且独特的受体酪氨酸激酶，它与细胞外基质的主要成分胶原蛋白结合。DDR1被证实可介导细胞聚集，DDR2的失调也被证明与肿瘤发病机制有关，尽管其在癌症发生和发展中的作用仍存在争议。
总结
DDR2在多种癌症类型中存在异常表达和突变，并且参与肿瘤进展的不同方面，包括增殖、迁移、侵袭、转移、上皮-间质转化和化疗耐药。此外，新型DDR2抑制剂已被设计出来，并显示出对癌症治疗的疗效。
关键信息
在本综述中，我们总结了目前关于DDR2在癌症促进中的作用以及靶向DDR2的潜在治疗价值的知识。
Zotero 插件